{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:17:51Z","timestamp":1788214671344,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"36","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,9,22]]},"DOI":"10.1038\/s41388-026-03900-y","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:56:57Z","timestamp":1785340617000},"page":"3842-3857","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer"],"prefix":"10.1038","volume":"45","author":[{"given":"Yingyin","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aochu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaomin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladi","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongle","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-3912","authenticated-orcid":false,"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5774-8568","authenticated-orcid":false,"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"3900_CR1","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","volume":"41","author":"JE Hawley","year":"2023","unstructured":"Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell. 2023;41:1972\u201388.e5.","journal-title":"Cancer Cell"},{"key":"3900_CR2","doi-asserted-by":"publisher","first-page":"5730.","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.","journal-title":"Molecules"},{"key":"3900_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06915-z","volume":"15","author":"L Shao","year":"2024","unstructured":"Shao L, Yu H, Wang M, Chen L, Ji B, Wu T, et al. DKK1-SE recruits AP1 to activate the target gene DKK1 thereby promoting pancreatic cancer progression. Cell Death Dis. 2024;15:566.","journal-title":"Cell Death Dis"},{"key":"3900_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13072-023-00502-w","volume":"16","author":"RW Zhou","year":"2023","unstructured":"Zhou RW, Parsons RE. Etiology of super-enhancer reprogramming and activation in cancer. Epigen Chromatin. 2023;16:29.","journal-title":"Epigen Chromatin"},{"key":"3900_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153:307\u201319.","journal-title":"Cell"},{"key":"3900_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrc.2016.62","volume":"16","author":"I Sur","year":"2016","unstructured":"Sur I, Taipale J. The role of enhancers in cancer. Nat Rev Cancer. 2016;16:483\u201393.","journal-title":"Nat Rev Cancer"},{"key":"3900_CR7","doi-asserted-by":"publisher","first-page":"2866.","DOI":"10.3390\/cancers14122866","volume":"14","author":"SC Tang","year":"2022","unstructured":"Tang SC, Vijayakumar U, Zhang Y, Fullwood MJ. Super-enhancers, phase-separated condensates, and 3D genome organization in cancer. Cancers (Basel). 2022;14:2866.","journal-title":"Cancers (Basel)"},{"key":"3900_CR8","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andr\u00e9 V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155:934\u201347.","journal-title":"Cell"},{"key":"3900_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70\u201380.","journal-title":"Blood"},{"key":"3900_CR10","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346\u201360.e7.","journal-title":"Cancer Cell"},{"key":"3900_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s12276-020-0428-7","volume":"52","author":"Q Jia","year":"2020","unstructured":"Jia Q, Chen S, Tan Y, Li Y, Tang F. Oncogenic super-enhancer formation in tumorigenesis and its molecular mechanisms. Exp Mol Med. 2020;52:713\u201323.","journal-title":"Exp Mol Med"},{"key":"3900_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202\u201316.","journal-title":"Cancer Discov"},{"key":"3900_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.molcel.2016.10.021","volume":"64","author":"CA Ishak","year":"2016","unstructured":"Ishak CA, Marshall AE, Passos DT, White CR, Kim SJ, Cecchini MJ, et al. An RB-EZH2 complex mediates silencing of repetitive DNA sequences. Mol Cell. 2016;64:1074\u201387.","journal-title":"Mol Cell"},{"key":"3900_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00277-9","volume":"9","author":"T Zhang","year":"2020","unstructured":"Zhang T, Song X, Zhang Z, Mao Q, Xia W, Xu L, et al. Aberrant super-enhancer landscape reveals core transcriptional regulatory circuitry in lung adenocarcinoma. Oncogenesis. 2020;9:92.","journal-title":"Oncogenesis"},{"key":"3900_CR15","doi-asserted-by":"publisher","first-page":"11434","DOI":"10.1093\/nar\/gkaa901","volume":"48","author":"X Shi","year":"2020","unstructured":"Shi X, Zheng Y, Jiang L, Zhou B, Yang W, Li L, et al. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma. Nucleic Acids Res. 2020;48:11434\u201351.","journal-title":"Nucleic Acids Res"},{"key":"3900_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccr.2012.11.010","volume":"23","author":"NL Sharma","year":"2013","unstructured":"Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, et al. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 2013;23:35\u201347.","journal-title":"Cancer Cell"},{"key":"3900_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317\u201331.","journal-title":"Cell"},{"key":"3900_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520:57\u201362.","journal-title":"Nature"},{"key":"3900_CR19","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018;20:1181\u201392.","journal-title":"Nat Cell Biol"},{"key":"3900_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280\u201396.","journal-title":"Nat Rev Clin Oncol"},{"key":"3900_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/nar\/gky1207","volume":"47","author":"L Lin","year":"2019","unstructured":"Lin L, Huang M, Shi X, Mayakonda A, Hu K, Jiang YY, et al. Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1. Nucleic Acids Res. 2019;47:1255\u201367.","journal-title":"Nucleic Acids Res"},{"key":"3900_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/bs.mcb.2021.01.001","volume":"163","author":"SH Sagheer","year":"2021","unstructured":"Sagheer SH, Whitaker-Menezes D, Han JYS, Curry JM, Martinez-Outschoorn U, Philp NJ. 4NQO induced carcinogenesis: a mouse model for oral squamous cell carcinoma. Methods Cell Biol. 2021;163:93\u2013111.","journal-title":"Methods Cell Biol"},{"key":"3900_CR23","doi-asserted-by":"publisher","first-page":"e01284.","DOI":"10.1002\/advs.202501284","volume":"12","author":"L Jiang","year":"2025","unstructured":"Jiang L, Wang J, Peng G, Zhang H, Fang J, Gao Y, et al. A super-enhancer-driven transcriptional regulatory circuit underlying abiraterone resistance in castration-resistant prostate cancer. Adv Sci (Weinh). 2025;12:e01284.","journal-title":"Adv Sci (Weinh)"},{"key":"3900_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","volume":"637","author":"A Lyu","year":"2025","unstructured":"Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, et al. Evolution of myeloid-mediated immunotherapy resistance in prostate cancer. Nature. 2025;637:1207\u201317.","journal-title":"Nature"},{"key":"3900_CR25","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41588-022-01168-y","volume":"54","author":"SC Baca","year":"2022","unstructured":"Baca SC, Singler C, Zacharia S, Seo JH, Morova T, Hach F, et al. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nat Genet. 2022;54:1364\u201375.","journal-title":"Nat Genet"},{"key":"3900_CR26","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1111\/1751-7915.14131","volume":"15","author":"S Huang","year":"2022","unstructured":"Huang S, Xue Y, Zhou C, Ma Y. An efficient CRISPR\/Cas9-based genome editing system for alkaliphilic Bacillus sp. N16-5 and application in engineering xylose utilization for D-lactic acid production. Micro Biotechnol. 2022;15:2730\u201343.","journal-title":"Micro Biotechnol"},{"key":"3900_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56714-z","volume":"16","author":"W Jiang","year":"2025","unstructured":"Jiang W, Guan B, Sun H, Mi Y, Cai S, Wan R, et al. WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis. Nat Commun. 2025;16:1429.","journal-title":"Nat Commun"},{"key":"3900_CR28","first-page":"142.","volume":"9","author":"ED Arisan","year":"2020","unstructured":"Arisan ED, Rencuzogullari O, Keskin B, Grant GH, Uysal-Onganer P. Inhibition on JNK mimics silencing of Wnt-11 mediated cellular response in androgen-independent prostate cancer cells. Biology (Basel). 2020;9:142.","journal-title":"Biology (Basel)"},{"key":"3900_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-55","volume":"9","author":"P Uysal-Onganer","year":"2010","unstructured":"Uysal-Onganer P, Kawano Y, Caro M, Walker MM, Diez S, Darrington RS, et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer. 2010;9:55.","journal-title":"Mol Cancer"},{"key":"3900_CR30","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"3900_CR31","doi-asserted-by":"publisher","first-page":"1999.","DOI":"10.3390\/cells13231999","volume":"13","author":"ZR Maylin","year":"2024","unstructured":"Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells. 2024;13:1999.","journal-title":"Cells"},{"key":"3900_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111123","volume":"40","author":"HS Sandhu","year":"2022","unstructured":"Sandhu HS, Portman KL, Zhou X, Zhao J, Rialdi A, Sfakianos JP, et al. Dynamic plasticity of prostate cancer intermediate cells during androgen receptor-targeted therapy. Cell Rep. 2022;40:111123.","journal-title":"Cell Rep"},{"key":"3900_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2023.106493","volume":"166","author":"KK Sruthi","year":"2024","unstructured":"Sruthi KK, Natani S, Ummanni R. Tumor protein D52 (isoform 3) induces NF-\u03baB - STAT3 mediated EMT driving neuroendocrine differentiation of prostate cancer cells. Int J Biochem Cell Biol. 2024;166:106493.","journal-title":"Int J Biochem Cell Biol"},{"key":"3900_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110595","volume":"39","author":"H Han","year":"2022","unstructured":"Han H, Wang Y, Curto J, Gurrapu S, Laudato S, Rumandla A, et al. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Rep. 2022;39:110595.","journal-title":"Cell Rep"},{"key":"3900_CR35","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3900_CR36","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 2016;22:298\u2013305.","journal-title":"Nat Med"},{"key":"3900_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105305","volume":"164","author":"X Zhou","year":"2021","unstructured":"Zhou X, Zou L, Chen W, Yang T, Luo J, Wu K, et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharm Res. 2021;164:105305.","journal-title":"Pharm Res"},{"key":"3900_CR38","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","volume":"174","author":"DY Takeda","year":"2018","unstructured":"Takeda DY, Spis\u00e1k S, Seo JH, Bell C, O\u2019Connor E, Korthauer K, et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell. 2018;174:422\u201332.e13.","journal-title":"Cell"},{"key":"3900_CR39","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510:278\u201382.","journal-title":"Nature"},{"key":"3900_CR40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320\u201334.","journal-title":"Cell"},{"key":"3900_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100859","volume":"36","author":"FN Grigore","year":"2023","unstructured":"Grigore FN, Yang SJ, Chen CC, Koga T. Pioneering models of pediatric brain tumors. Neoplasia. 2023;36:100859.","journal-title":"Neoplasia"},{"key":"3900_CR42","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-023-02776-0","volume":"42","author":"L Yin","year":"2023","unstructured":"Yin L, Ye Y, Zou L, Lin J, Dai Y, Fu Y, et al. AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer. J Exp Clin Cancer Res. 2023;42:204.","journal-title":"J Exp Clin Cancer Res"},{"key":"3900_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"3900_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"JN Anastas","year":"2013","unstructured":"Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11\u201326.","journal-title":"Nat Rev Cancer"},{"key":"3900_CR45","doi-asserted-by":"publisher","first-page":"a007914.","DOI":"10.1101\/cshperspect.a007914","volume":"4","author":"R van Amerongen","year":"2012","unstructured":"van Amerongen R. Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol. 2012;4:a007914.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"3900_CR46","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.cell.2017.05.016","volume":"169","author":"R Nusse","year":"2017","unstructured":"Nusse R, Clevers H. Wnt\/\u03b2-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985\u201399.","journal-title":"Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03900-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03900-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03900-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:02:46Z","timestamp":1788213766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03900-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":46,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2026,9,22]]}},"alternative-id":["3900"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03900-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The adjacent, PC and CRPC tissue in this study were obtained from the Department of Urology, the Third Affiliated Hospital of Guangzhou Medical University (Guangzhou, Guangdong, China), which was approved by the medical research ethics committee review (approve number: 2024-008), with the permission of the patients. The animal experiments were subjected to the approval of the Experimental Animal Ethics Committee of Guangzhou Medical University (approve number: GY2022179).","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors approved for the publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}